Composition of matter and methods of use claims encompass EB-373, Enveric’s new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder This new patent, issued July 25, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder Enveric Biosciences ENVB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback